2019
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
Sarnaik A, Thomas S, Davar D, Kirkwood J, Kluger H, Lutzky J, Wilson M, Pavlick A, Curti B, Whitman E, Phan G, Ernstoff M, Takamura K, Barton D, Suzuki S, Karyampudi L, Samberg N, Fardis M, Chesney J. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy. Journal Of Clinical Oncology 2019, 37: 136-136. DOI: 10.1200/jco.2019.37.8_suppl.136.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesBRAF/MEK inhibitorsMetastatic melanoma patientsMetastatic melanomaPrior therapyCheckpoint inhibitorsMelanoma patientsIL-2Advanced metastatic melanoma patientsHigh-dose IL-2MEK inhibitorsBaseline tumor burdenCohort 2 patientsDose IL-2Frequency of AEsPrior systemic therapyAdoptive cell therapyUnresectable metastatic melanomaPreliminary dataAutologous tumorLymphodepletion regimenTIL treatmentMedian followProgressive diseaseComplete response
2017
Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.
Sarnaik A, Kluger H, Chesney J, Sethuraman J, Veerapathran A, Simpson-Abelson M, Lotze M, Larsen B, Fischkoff S, Suzuki S, Wang L, Mirgoli M, Fardis M, Curti B. Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy. Journal Of Clinical Oncology 2017, 35: 3045-3045. DOI: 10.1200/jco.2017.35.15_suppl.3045.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesAdvanced metastatic melanomaMetastatic melanomaTIL productsPrior therapySafety profileIL-2Advanced metastatic melanoma patientsNon-hematologic grade 3Cell therapyPrior systemic therapyAcceptable safety profilePhase 2 studyMetastatic melanoma patientsAdoptive cell therapyEx vivo expansionEnlisted patientsRECIST 1.1Study patientsCheckpoint therapyMedian durationSurgical resectionSystemic therapyAutologous lymphocytesMedian age
2016
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells
Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight 2016, 1: e88955. PMID: 28018970, PMCID: PMC5161225, DOI: 10.1172/jci.insight.88955.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesMemory T cellsTissue-resident memory T cellsT cell receptorImmune checkpointsT cellsIndividual metastasesSubset of TILsExpression of ICsCell receptorTumor cellsLess IL-2Blood T cellsExpression of VEGFTIL infiltrationDurable responsesAdvanced melanomaImmune therapyNeoantigen loadIL-2Immune cellsNonlymphoid tissuesSame patientMyeloid cellsMetastasis